Research Groups and R&D Platforms: In Vivo Diagnostics
R&D Platform:
Turku BioImaging
Turku BioImaging, TBI (www.bioimaging.fi), is an umbrella organization for “all things imaging” in Turku, jointly operated by Åbo Akademi University and the University of Turku. TBI was initiated in 2007 as a broad-based, interdisciplinary imaging consortium that aims at bringing together all biological and medical imaging expertise in Turku and elsewhere in Finland. In 2017, Turku BioImaging is celebrating its journey of 10 years, from a small 2-person unit to a large, fully functioning organization.
Atomic-force microscopy, Basic research, Clinical development, Diagnostics, Electron microscopy, FTIR or RAMAN microscopy, High throughput imaging, Imaging, Imaging software, In Vivo Diagnostics, PET, Preclinical development, R&D Platforms, Super-resolution imaging, Ultrasound imaging
R&D Platform:
Cancer Centre of the Turku University Hospital
The Tyks Cancer Centre guarantees high-quality cancer treatment and research in the hospital districts of Southwest Finland, Satakunta and Vaasa.
The Tyks Cancer Centre works to unify treatment practices and treatment quality, and to see to it that patients get access to treatment according to unified criteria in a timely manner in the western coastal area of Finland. This puts the patients with cancer at the right place at the right time, regardless of where they live.
The Tyks Cancer Centre is a part of the Cancer Center Finland (FICAN) – a national enterprise under construction to coordinate cancer treatment, research and education in the whole of Finland.
Breast cancer, Cancer, Clinical development, Colorectal cancer, Diagnostics, In Vitro Diagnostics, In Vivo Diagnostics, Lung cancer, Melanoma, Ovarian cancer, Prostate cancer, R&D Platforms, Squamous cell carcinoma
Research Group:
Early detection of Alzheimer´s disease: a translational study
Juha Rinne
juha.rinne[at]tyks.fi
Turku PET Centre, University of Turku and
Division of Clinical Neurosciences, Turku University Hospital
Ageing-related diseases, Biomarker, Clinical development, Clinical Medicine, Diagnostics, Imaging, In Vivo Diagnostics, Molecular diagnostics, Neurological disorders, PET, Receptor
Research Group:
Imaging Alzheimer’s disease beta-amyloid pathology in transgenic mouse models using positron emission tomography
Francisco López-Picón
fralop[at]utu.fi
Turku PET Centre, Preclinical Imaging,
University of Turku
Ageing-related diseases, Biomarker, Biomedicine, Biopharmaceuticals, Clinical Medicine, Disease models, Drug delivery, Drug target, Epigenomics, Imaging, Imaging software, In Vitro Diagnostics, In Vivo Diagnostics, Inflammation, Molecular Biology, Molecular diagnostics, Neurological disorders, Pathology, PET, Pharmacology, Physiology, Preclinical development, Proteomics, Target discovery
Research Group:
PET imaging of neuropathological changes in animal models of Alzheimer’s disease
Merja Haaparanta-Solin
mehaaso[at]utu.fi
Turku PET Centre, Preclinical Imaging,
University of Turku
https://www.utu.fi/en/units/med/research/research_projects/Pages/merja-haaparanta-solin.aspx
Ageing-related diseases, Antibodies, Autoimmune diseases, Basic research, Biochemistry, Biomarker, Biomedicine, Cardiovascular diseases, Diabetes, Disease models, Drug target, Imaging, In Vitro Diagnostics, In Vivo Diagnostics, Inflammation, Metabolic diseases, Nanoparticles, Neurological disorders, Organic compounds, PET, Pharmacology, Preclinical development, Receptor, Target discovery
Research Group:
Molecular epidemiology, carriage and antimicrobial susceptibility of bacterial pathogens
Jaana Vuopio
jaana.vuopio[at]utu.fi
Department of Medical Microbiology and Immunology,
University of Turku
http://www.utu.fi/en/units/med/units/immunology/research/Pages/vuopio.aspx
Antibacterial, Antibodies, Bacteriology, Basic research, Bioinformatics, Biomarker, Biomedicine, Clinical Medicine, Data mining, Diagnostics, Epidemiology, Genetics, Genomics, Immunology, In Vitro Diagnostics, In Vivo Diagnostics, Infection, Inflammation, Molecular diagnostics, Next-generation sequencing, Nucleic acids, Personalized medicine, Point of care, Receptor
